Потребности, ожидания и сомнения у пользователей гормональными контрацептивами

1. Gambera A, Corda F, Papa R et al. Observational, prospective, multicentre study to evaluate the effects of counselling on the choice of combined hormonal contraceptives in Italy – the ECOS (Educational COunselling effectS) study. BMC Womens Health 2015; 15: 69. DOI: 10.1186/s12905-015-0226-x
2. Egarter C, Frey Tirri B et al. Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Womens Health 2013; 13: 9. DOI: 10.1186/1472-6874-13-9
3. Дикке Г.Б. Пять шагов к успешной контрацепции. Руководство для врачей. М.: Академия Естествознания, 2017.
 [Dikke G.B. Five steps to successful contraception: a guide for doctors. Moscow: Academy of Natural Sciences, 2017 (in Russian).]
4. Сакевич В.И. Аборты в мире: неравномерная динамика и неравный доступ. Демоскоп Weekly. 2018; 773–774. http://demoscope.ru/
 [Sakevich V.I. Abortions in the world: uneven dynamics and unequal access. Demoscope Weekly. 2018; 773–774. http://demoscope.ru/ (in Russian).]
5. Дикке Г.Б., Ерофеева Л.В. Контрацепция в современной России: применение и информированность (популяционное исследование). Акушерство и гинекология. 2016; 2: 108–13. DOI: 10.18565/aig.2016.2.108-113
 [Dikke G.B., Erofeeva L.V. Contraception in modern Russia: use and awareness (population study). Obstetrics and gynecology/Akusherstvo i ginekologiya. 2016; 2: 108–13. DOI: 10.18565/aig.2016.2.108-113 (in Russian).]
6. FIGO. The global unmet need for modern contraceptives. 26.09.2018. https://www.figo.org
7. Hooper DJ. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin Drug Investig 2010; 30: 749–63.
8. Довлетханова Э.Р., Прилепская В.Н. Эстрадиола валерат и диеногест в гормональной контрацепции: приемлемость и эффективность в реальной клинической практике. Мед. совет. 2018: 13: 34–8. DOI: 10.21518/2079-701X-2018-13-34-38
 [Dovletkhanova E.R., Prilepskaia V.N. Estradiola valerat i dienogest v gormonal'noi kontratseptsii: priemlemost' i effektivnost' v real'noi klinicheskoi praktike. Med. sovet. 2018: 13: 34–8. DOI: 10.21518/2079-701X-2018-13-34-38 (in Russian).]
9. Ahrendt HJ, Makalová D, Parke S et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 2009; 80 (5): 436–44. DOI: 10.1016/j.contraception.2009.03.018
10. Fruzzetti F, Paoletti AM, Fidecicchi T et al. Contraception with estradiol valerate and dienogest: adherence to the method. Open Access
J Contracept 2019; 10: 1–6. DOI: 10.2147/OAJC.S204655
11. Fraser IS, Parke S, Mellinger U et al. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2011; 16 (4): 258–69. DOI: 10.3109/13625187.2011.591456
12. Briggs P, Serrani M, Vogtländer K, Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. Int J Womens Health 2016; 8: 477–87. eCollection 2016
13. Premenstrual syndrome: Overview. In: Informed Health Online. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG), 2017. https://www.ncbi.nlm.nih.gov/books/NBK279265/
14. Cooper DB, Adigun R. Oral Contraceptive Pills. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2018. https://www.ncbi.nlm.nih.gov/books/NBK430882//
15. Nappi RE, Nappi G. Neuroendocrine aspects of migraine in women. Gynecol Endocrinol 2012; 28: 37–41. DOI: 10.3109/09513590.2012.651931
16. Mabey Jr RG, Parke S, Mellinger U et al. Hormone withdrawal-associated symptoms: comparison of estradiol valerate/dienogest versus ethinylestradiol/norgestimate. Abstract plus poster presentation at the 60th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists; 2012 May 5–9; San Diego, CA. Eur
J Contracept Reprod Health Care 2013; 18 (4): 274–83. DOI: 10.3109/13625187.2013.785516
17. Jensen JT, Parke S, Mellinger U et al. Hormone withdrawal-associated symptoms: Comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate. Eur J Contracep Reprod Health Care 2013; 18 (4): 274–83. DOI: 10.3109/13625187.2013.785516
18. Macìas G, Merki-Feld GS, Parke S et al. Hormone withdrawal-associated symptoms in women taking combined oral contraceptives: comparison of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Abstract plus poster presentation at the 15th World Congress on Gynecological Endocrinology; 2012 March 7–10; Firenze, Italy.
19. Macìas G, Merki-Feld S, Parke S et al. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: Results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J Obstet Gynaecol 2013; 33: 591–6. DOI: 10.3109/01443615.2013.800851
20. Graziottin A. The shorter, the better: A review of the evidence for a shorter contraceptive hormone-free interval. Eur J Contracept Reprod Health Care 2016; 21 (2): 93–105. DOI: 10.3109/13625187.2015.1077380
21. Grandi G, Xholli A, Napolitano A et al. Prospective measurement of blood pressure and heart rate over 24 h in women using combined oral contraceptives with estradiol. Contraception 2014; 90 (5): 529–34. DOI: 10.1016/j.contraception.2014.05.011
22. Paoletti AM, Lello S, Di Carlo C et al. Effect of Estradiol valerate plus dienogest on body composition of healthy women in the menopausal transition: a prospective one-year evaluation. Gynecol Endocr 2016; 32 (1): 61–4. DOI: 10.3109/09513590.2015.1079175
23. Junge W, Mellinger U, Parke S, Serrani M. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig 2011; 31 (8): 573–84. DOI: 10.2165/11590220-000000000-00000
24. Grandi G, Piacenti I, Volpe A, Cagnacci A. Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl estradiol. Gynecol Endocrinol 2014; 30 (9): 676–80. DOI: 10.3109/09513590.2014.922947
25. De Leo V, Fruzzetti F, Musacchio MC et al. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Contraception 2013; 88 (3): 364–8. DOI: 10.1016/j.contraception.2012.09.003
26. Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016; 94 (4): 328–39. DOI: 0.1016/j.contraception.2016.06.010
27. Wallwiener CW, Wallwiener L-M, Seeger H et al. Are hormonal components of oral contraceptives associated with impaired female sexual function? A questionnaire-based online survey of medical students in Germany, Austria, and Switzerland. Arch Gynecol Obstet 2015; 292 (4): 883–90. DOI: 10.1007/s00404-015-3726-x
28. Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review. Eur J Contracept Reprod Health Care 2013; 18 (1): 27–43. DOI: 10.3109/13625187.2012.728643
29. Casado-Espada NM, de Alarcón R, de la Iglesia-Larrad JI et al. Hormonal Contraceptives, Female Sexual Dysfunction, and Managing Strategies: A Review. J Clin Med 2019; 8 (6): 908. DOI: 10.3390/jcm8060908
30. Higgins JA, Smith NK. The Sexual Acceptability of Contraception: Reviewing the Literature and Building a New Concept. J Sex Res 2016; 53 (4–5): 417–56. DOI: 10.1080/00224499.2015.1134425
31. Davis SR, Bitzer J, Giraldi A et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J Sex Med 2013; 10: 3069–79. DOI: 10.1111/jsm.12310
32. Caruso S, Agnello C, Romano M et al. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J Sex Med 2011; 8 (10): 2841–50. DOI: 10.1111/j.1743-6109.2011.02409.x
33. De Seta F, Restaino S, Banco R et al. Effects of estroprogestins containing natural estrogen on vaginal flora. Gynecol Endocrinol 2014; 30 (11): 830–5. DOI: 10.3109/09513590.2014.936847
34. Nelson A, Parke S, Makalova D et al. Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: a pooled analysis of three studies conducted in North America and Europe. Eur J Contracept Reprod Health Care 2013; 18 (4): 264–73. DOI: 10.3109/13625187.2013.780202
35. Barnett C, Dinger J, Minh TD, Heinemann K. Unintended pregnancy rates differ according to combined oral contraceptive – results from the INAS-SCORE study. Eur J Contracept Reprod Health Care 2019; 24 (4): 247–50. DOI: 10.1080/13625187.2019.1629412

________________________________________________

1. Gambera A, Corda F, Papa R et al. Observational, prospective, multicentre study to evaluate the effects of counselling on the choice of combined hormonal contraceptives in Italy – the ECOS (Educational COunselling effectS) study. BMC Womens Health 2015; 15: 69. DOI: 10.1186/s12905-015-0226-x
2. Egarter C, Frey Tirri B et al. Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Womens Health 2013; 13: 9. DOI: 10.1186/1472-6874-13-9
3. Dikke G.B. Five steps to successful contraception: a guide for doctors. Moscow: Academy of Natural Sciences, 2017 (in Russian).
4. Sakevich V.I. Abortions in the world: uneven dynamics and unequal access. Demoscope Weekly. 2018; 773–774. http://demoscope.ru/ (in Russian).
5. Dikke G.B., Erofeeva L.V. Contraception in modern Russia: use and awareness (population study). Obstetrics and gynecology/Akusherstvo i ginekologiya. 2016; 2: 108–13. DOI: 10.18565/aig.2016.2.108-113 (in Russian).
6. FIGO. The global unmet need for modern contraceptives. 26.09.2018. https://www.figo.org
7. Hooper DJ. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin Drug Investig 2010; 30: 749–63.
8. Dovletkhanova E.R., Prilepskaia V.N. Estradiola valerat i dienogest v gormonal'noi kontratseptsii: priemlemost' i effektivnost' v real'noi klinicheskoi praktike. Med. sovet. 2018: 13: 34–8. DOI: 10.21518/2079-701X-2018-13-34-38 (in Russian).
9. Ahrendt HJ, Makalová D, Parke S et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 2009; 80 (5): 436–44. DOI: 10.1016/j.contraception.2009.03.018
10. Fruzzetti F, Paoletti AM, Fidecicchi T et al. Contraception with estradiol valerate and dienogest: adherence to the method. Open Access
J Contracept 2019; 10: 1–6. DOI: 10.2147/OAJC.S204655
11. Fraser IS, Parke S, Mellinger U et al. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2011; 16 (4): 258–69. DOI: 10.3109/13625187.2011.591456
12. Briggs P, Serrani M, Vogtländer K, Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. Int J Womens Health 2016; 8: 477–87. eCollection 2016
13. Premenstrual syndrome: Overview. In: Informed Health Online. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG), 2017. https://www.ncbi.nlm.nih.gov/books/NBK279265/
14. Cooper DB, Adigun R. Oral Contraceptive Pills. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2018. https://www.ncbi.nlm.nih.gov/books/NBK430882//
15. Nappi RE, Nappi G. Neuroendocrine aspects of migraine in women. Gynecol Endocrinol 2012; 28: 37–41. DOI: 10.3109/09513590.2012.651931
16. Mabey Jr RG, Parke S, Mellinger U et al. Hormone withdrawal-associated symptoms: comparison of estradiol valerate/dienogest versus ethinylestradiol/norgestimate. Abstract plus poster presentation at the 60th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists; 2012 May 5–9; San Diego, CA. Eur
J Contracept Reprod Health Care 2013; 18 (4): 274–83. DOI: 10.3109/13625187.2013.785516
17. Jensen JT, Parke S, Mellinger U et al. Hormone withdrawal-associated symptoms: Comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate. Eur J Contracep Reprod Health Care 2013; 18 (4): 274–83. DOI: 10.3109/13625187.2013.785516
18. Macìas G, Merki-Feld GS, Parke S et al. Hormone withdrawal-associated symptoms in women taking combined oral contraceptives: comparison of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Abstract plus poster presentation at the 15th World Congress on Gynecological Endocrinology; 2012 March 7–10; Firenze, Italy.
19. Macìas G, Merki-Feld S, Parke S et al. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: Results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J Obstet Gynaecol 2013; 33: 591–6. DOI: 10.3109/01443615.2013.800851
20. Graziottin A. The shorter, the better: A review of the evidence for a shorter contraceptive hormone-free interval. Eur J Contracept Reprod Health Care 2016; 21 (2): 93–105. DOI: 10.3109/13625187.2015.1077380
21. Grandi G, Xholli A, Napolitano A et al. Prospective measurement of blood pressure and heart rate over 24 h in women using combined oral contraceptives with estradiol. Contraception 2014; 90 (5): 529–34. DOI: 10.1016/j.contraception.2014.05.011
22. Paoletti AM, Lello S, Di Carlo C et al. Effect of Estradiol valerate plus dienogest on body composition of healthy women in the menopausal transition: a prospective one-year evaluation. Gynecol Endocr 2016; 32 (1): 61–4. DOI: 10.3109/09513590.2015.1079175
23. Junge W, Mellinger U, Parke S, Serrani M. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig 2011; 31 (8): 573–84. DOI: 10.2165/11590220-000000000-00000
24. Grandi G, Piacenti I, Volpe A, Cagnacci A. Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl estradiol. Gynecol Endocrinol 2014; 30 (9): 676–80. DOI: 10.3109/09513590.2014.922947
25. De Leo V, Fruzzetti F, Musacchio MC et al. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Contraception 2013; 88 (3): 364–8. DOI: 10.1016/j.contraception.2012.09.003
26. Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016; 94 (4): 328–39. DOI: 0.1016/j.contraception.2016.06.010
27. Wallwiener CW, Wallwiener L-M, Seeger H et al. Are hormonal components of oral contraceptives associated with impaired female sexual function? A questionnaire-based online survey of medical students in Germany, Austria, and Switzerland. Arch Gynecol Obstet 2015; 292 (4): 883–90. DOI: 10.1007/s00404-015-3726-x
28. Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review. Eur J Contracept Reprod Health Care 2013; 18 (1): 27–43. DOI: 10.3109/13625187.2012.728643
29. Casado-Espada NM, de Alarcón R, de la Iglesia-Larrad JI et al. Hormonal Contraceptives, Female Sexual Dysfunction, and Managing Strategies: A Review. J Clin Med 2019; 8 (6): 908. DOI: 10.3390/jcm8060908
30. Higgins JA, Smith NK. The Sexual Acceptability of Contraception: Reviewing the Literature and Building a New Concept. J Sex Res 2016; 53 (4–5): 417–56. DOI: 10.1080/00224499.2015.1134425
31. Davis SR, Bitzer J, Giraldi A et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J Sex Med 2013; 10: 3069–79. DOI: 10.1111/jsm.12310
32. Caruso S, Agnello C, Romano M et al. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J Sex Med 2011; 8 (10): 2841–50. DOI: 10.1111/j.1743-6109.2011.02409.x
33. De Seta F, Restaino S, Banco R et al. Effects of estroprogestins containing natural estrogen on vaginal flora. Gynecol Endocrinol 2014; 30 (11): 830–5. DOI: 10.3109/09513590.2014.936847
34. Nelson A, Parke S, Makalova D et al. Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: a pooled analysis of three studies conducted in North America and Europe. Eur J Contracept Reprod Health Care 2013; 18 (4): 264–73. DOI: 10.3109/13625187.2013.780202
35. Barnett C, Dinger J, Minh TD, Heinemann K. Unintended pregnancy rates differ according to combined oral contraceptive – results from the INAS-SCORE study. Eur J Contracept Reprod Health Care 2019; 24 (4): 247–50. DOI: 10.1080/13625187.2019.1629412

Г.Б. Дикке*

ЧОУ ДПО «Академия медицинского образования им. Ф.И. Иноземцева», Санкт-Петербург, Россия
*galadikke@yandex.ru

________________________________________________

Galina B. Dikke*

Inozemtsev Academy of Medical Education, Saint Petersburg, Russia
*galadikke@yandex.ru